CRM Research Update — August 28, 2026 (Updated)
Updated Thesis
Salesforce is the leading enterprise CRM platform, selling sales, service, marketing, commerce, data and AI-agent software through a deeply embedded application stack and partner ecosystem. Business quality is solid, supported by a 20.0% worldwide CRM revenue share in 2025, 77.3% TTM gross margin, 21.4% TTM operating margin, 22.0% TTM net margin and 20.2% ROE. Revenue grew 10.8% year over year in the most recent quarter, while earnings grew 86.9% year over year in the most recent quarter, although reported GAAP earnings were materially aided by strategic-investment gains.
The investment grade as of this refresh is B — solid business quality. Medium-tier business, cheap-tier valuation, with 8.7% upside to $265.50 fair value.
Key Metrics at a Glance
- Revenue growth: +10.8% year over year
- Net margin: 22.0%
- Fair value upside: +8.7% to our estimate of $266
Current price: $244.16
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Salesforce, Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full CRM research →](/stocks/CRM)